The AAPM Medical Physics Practice Guideline (MPPG) 5.a provides concise guidance on the commissioning and QA of beam modeling and dose calculation in radio- 
respectively, to provide comprehensive guidelines for acceptance testing, commissioning, and ongoing quality assurance of 3D TPS.
Starkschall et al. 5 described a beam modeling methodology for the convolution/superposition dose calculation algorithm in the Pinnacle TPS, including an assessment of model accuracy using the recommended procedures in TG-53. In 2001, Venselaar et al. 6 proposed a set of tests and appropriate tolerances for photon beam dose calculations. In addition, validation tests for nonstandard treatment geometries, inhomogeneous media, MLC modeling, and commissioning have been described. [7] [8] [9] The A number of previous studies discussed the development of custom tools for automated analysis of commissioning data. Adnani 12 designed a TG-106 compliant linear accelerator data management system for physics data acquisition, processing, and validation. Birgani et al. 13 created a MATLAB program for comparing commissioning measurements and dose distributions from a custom-made second-check software. Bergman et al. 14 
| METHODS
The MPPG 5.a report intentionally allows for flexibility in data acquisition, tools, and processes. The measured data can be acquired with a variety of detectors in solid phantoms, planar or volumetric QA devices, or a scanning water tank. The measurement tools used for this project are summarized in Table 1 algorithm for electrons. The Eclipse photon dose was calculated with both "AAA" and "Acuros XB." The electron dose was calculated with the "eMC" algorithm.
2.B | Measurements for profile tests
Scanning water tank measurements were used for a number of The MLC field shapes for the basic photon tests in section 5 of MPPG 5.a are illustrated in Fig. 2 the 3D DICOM-RT Dose file using a 3D cubic interpolation algorithm. Finally, the two profiles (measured and calculated) are compared using a 1D gamma analysis according to the technique described by Low et al. 20 The user may specify a number of analysis settings, including gamma analysis options and normalization methods.
The program has an easy-to-use graphical user interface (Fig. 5) .
A sample output from the PCT is shown in Fig. 6 and includes 
2.D | Measurements and analysis for nonprofile tests
The point dose measurement tests (5.2, 6.2, 7.2 and 8.3) are relatively straightforward, and the measurement data were easily analyzed using our spreadsheet. Test 5.2 is an important test to verify the absolute dose specification in the planning system. A beam equivalent to the calibration geometry (e.g., 10 9 10 cm 2 at 100 cm SSD) was created in the TPS to ensure that the dose per MU matches the measured value at the calibration depth (e.g., 10 cm). | 121
(electrons) are used in this work. For IMRT/VMAT evaluation, we used the evaluation criteria listed in MPPG 5.a. (Table 8 ).
| RESULTS
The validation tests outlined in MPPG 5.a were performed at two institutions with newly created tools. The validation experience resulted in more than 200 water tank scans and more than 50 point measurements per institution. Time estimates for preparation, measurement, and analysis activities are summarized in Table 2 . Time estimates for each test are summarized in Table 3 
3.A | MPPG 5.a tests with tolerance values
The results of all the validation tests in MPPG 5.a sections 5 and 8 meet the tolerances for the basic photon and electron models for both the Pinnacle and Eclipse TPS. Similarly, the results from the heterogeneity correction tests in sections 6 and 8 also meet the tolerances suggested in MPPG 5.a. One of the benefits of using the PCT for analyzing the basic photon and electron tests is that it allowed us to discover characteristics of our models that are not explicitly evaluated using the MPPG 5.a tolerances. The PCT also allowed us to discover dose discrepancies in our electron models that were not uncovered using the MPPG 5.a tolerances. For example, two of the measured PDDs for the small cutout in test 8.1 showed dose discrepancies for Pinnacle beyond R 50 , which resulted in gamma passing rates below 95%. An example is shown in Fig. 8 . The other PDDs for the small cutout exhibited a similar discrepancy, but the magnitude was small enough that the (2) an objective of the validation tests is to reveal weaknesses in the models. We evaluated the tests in section 7 using gamma criteria of 2%/2 mm and 3%/ 3 mm. (Figs 3b and 3c) , neither of which provide charged particle equilibrium near the peak dose. Consequently, the measurement locations were in high-dose/high-gradient regions.
There was no corresponding tolerance or evaluation criteria listed in the guideline for this situation ( the PCT was exceptionally valuable because it could be run quickly using multiple gamma criteria. The tests at both institutions found gamma passing rates exceeding 95% at 2%/2 mm for the PDDs and the high-dose region of the profiles. However, the validation testing revealed limitations with the out-of-field dose modeling for Eclipse, which required us to reanalyze the profiles at 3%/3 mm to verify that the out-of-field dose agreement met the tolerance specified in MPPG 5.a. For Eclipse, the out-of-field dose modeling was poor for both the AAA and the Acuros XB algorithm, but the results were worse for Acuros XB. The out-of-field dose modeling showed the greatest discrepancy between measurement and calculation at deeper depths. Underestimation of out-of-field dose has been documented in the literature for both Eclipse AAA 21, 22 and Pinnacle. 23 These studies report local dose differences in the out-of-field region as large as 50%. To our knowledge, our study is the first to indicate the underestimation of out-of-field dose may be worse for Eclipse Acuros XB than AAA. Accurate modeling of the out-of-field dose can be critical when calculating dose for certain treatment situations, including fetal dose or implantable cardiac devices.
Test 6.1 verified that the HU-value-to-density calibration was appropriately applied for both TPS. Test 6.2, which validates heterogeneity corrections for photon beams, was a simple and useful test. The Eclipse AAA and Pinnacle CS algorithms were accurate to within 2% for all energies both above and below the heterogeneity.
Due to the unique characteristics of Acuros XB, results of test 6.2 depend upon whether the phantom materials were overridden to non-biological materials in the TPS. The Eclipse Acuros XB algorithm assigns biological materials to each voxel in the CT dataset. 24 When the dose calculation was performed on the phantom using the doseto-medium reporting method and no material overrides, the dose differences exceeded 2%. For this dose calculation method, the dose at the ion chamber locations was calculated in a combination of "skeletal muscle" and "cartilage" materials that are automatically assigned by Acuros XB. The maximum difference between Acuros XB and the measured dose was 2.2% above the heterogeneity and 2.6% below the heterogeneity. The results improved significantly when the Solid
Water and cork regions in the TPS were overridden to the "water"
and "cork" materials, respectively. The maximum difference between Acuros XB and the measured dose was 1.3% above the heterogeneity and 0.6% below the heterogeneity when material overrides were used in the dose calculation. We learned that water-equivalent phantoms should be manually overridden to the "water" material for accurate dose calculation when using Acuros XB.
Pinnacle and Eclipse performed well on the small static field vali- 5.a. Our intention was to use shapes that were reminiscent of MLC segments in IMRT and VMAT plans. In practice, it is very difficult to measure output factors for these odd shapes due to the lack of charged particle equilibrium and the sensitivity of the measurement to detector positioning.
Tests 7.3-7.5 accounted for most of the testing time because the plans had to be optimized after the static field model was ready.
In addition, the model parameters for IMRT and VMAT typically needed to be iteratively adjusted, resulting in a more involved analysis process. Both institutions found that they could achieve excellent profile agreement for static fields, but that this was not sufficient for optimizing dosimetric agreement for IMRT and VMAT. Tests 7.3 and 7.4 were used to refine the MLC model parameters, including MLC transmission for both TPS; the dosimetric leaf-gap for Eclipse; and leaf tip radius, tongue-and-groove width, interleaf leakage transmission, and the rounded leaf offset table for Pinnacle.
Once these parameters were optimized, both institutions used clinical plans designed for test 7.4 to verify their beam models for IMRT and VMAT. We discovered that our models could not obtain the same level of agreement across the full range of field sizes used in clinical practice. In particular, we initially found that our models did not perform as well for IMRT and VMAT plans that treated large In addition to the overall validation of our clinical systems, the second objective of this project was to present tools and methods used by our institutions. The development of the PCT required a lot of work up front but proved to be an invaluable tool that efficiently analyzed a large volume of profile data using flexible evaluation criteria. It is our hope that by sharing this tool (and the accompanying spreadsheet), others can add to its utility and ease of use. Test design is another important aspect of MPPG 5.a. The guideline does not explicitly define test fields, but rather defines a limited scope of validation to be done. Initially, we considered tests that were more rigorous and beyond the scope of MPPG 5.a (e.g., measuring at additional electron depths and creating very small test shapes for 7.2).
As expected, these more challenging geometries highlighted weaknesses of the algorithms and the limits of our measurement abilities in very small fields. Ultimately, all of the validation tests showed that our algorithms met the widely accepted, published tolerances quoted in sections 5, 6, and 8 of MPPG 5.a. The use of a 2%/2 mm gamma criteria and more rigorous small field testing was a good complement to the limited dataset recommended by vendors for commissioning.
For users who wish to scrutinize their TPS models further, we recommend comparing your results to previous work on the topic of validation found in the literature. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Finally, we wanted to note what appears to be an error in MPPG 5.a to future users of the guideline. Table 8 in MPPG 5.a uses the term "tolerance" when it is clear from the text of the guideline (particularly section 1B) that the values are meant to be evaluation criteria. We suggest this column heading be changed to "evaluation criteria" to more accurately reflect the intent of the more rigorous IMRT/VMAT gamma criteria.
We recommend a slightly different organization of the tests in 
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